Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers

Justin Ferdinandus, Maximilian Buettner, John Stavliotis, Karolin Behringer, Mark Hertzberg, Helen Kaul, Peter Borchmann

Open source

DOI: 10.6084/m9.figshare.32266609.v1
Published: 2026
Container: Not recorded
Publisher: Taylor & Francis
Open access: yes

Credibility signals

limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.6084/m9.figshare.32266609.v1,
  title = {Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers},
  author = {Justin Ferdinandus and Maximilian Buettner and John Stavliotis and Karolin Behringer and Mark Hertzberg and Helen Kaul and Peter Borchmann},
  year = {2026},
  doi = {10.6084/m9.figshare.32266609.v1},
  url = {https://doi.org/10.6084/m9.figshare.32266609.v1}
}

RIS

TY  - JOUR
TI  - Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers
AU  - Justin Ferdinandus
AU  - Maximilian Buettner
AU  - John Stavliotis
AU  - Karolin Behringer
AU  - Mark Hertzberg
AU  - Helen Kaul
AU  - Peter Borchmann
PY  - 2026
DO  - 10.6084/m9.figshare.32266609.v1
UR  - https://doi.org/10.6084/m9.figshare.32266609.v1
ER  -

APA

Ferdinandus, J., Buettner, M., Stavliotis, J., Behringer, K., Hertzberg, M., Kaul, H., & Borchmann, P. (2026). Comparing a treatment combination that includes brentuximab vedotin with standard of care chemotherapy for treating advanced Hodgkin lymphoma: a plain language summary of the HD21 clinical study intended for patients and carers. https://doi.org/10.6084/m9.figshare.32266609.v1

Source records

datacite · retrieved 2026-09-26T10:06:56.097Z